Investing to become financially independent
Investing to become financially independent
Discover our detailed analysis of Becton Dickinson (BDX), the US leader in medical devices with a worldwide presence and over 50 years of consecutive dividend increases. An impressive defensive stock that has significantly outperformed the S&P 500, combining stable growth and low volatility for investors.
The persistent weakness of the dollar against the Swiss franc is impacting our investment portfolio, with a drop in profitability since February. Despite this delicate context, attractive investment opportunities remain, notably in defensive stocks such as Johnson & Johnson, while the US market is showing signs of overvaluation according to Warren Buffett's favorite indicator.
An analysis of Clorox's remarkable performance following Carl Icahn's investment, with a focus on its dividend strategy and stability in times of crisis. The portfolio shows marked improvement with volatility under control, thanks in particular to strategic investments such as Coca-Cola.
Find out why Enbridge, the Canadian oil and gas transmission giant, has been offering attractive long-term yields and growing dividends for 16 years. Despite its attractive dollar diversification benefits and low volatility, the high payout ratio of 67.30% currently prompts caution.
The portfolio is showing encouraging signs thanks to the simultaneous progress of the dollar and the market, despite remaining in the red. Strategic adjustments to the algorithm have been made to better manage currency risk, with a particular focus on stocks offering good resistance to dollar fluctuations.
Find out why Colgate-Palmolive, the US hygiene and household products giant, represents an attractive investment opportunity despite its recent underperformance. With iconic brands such as Colgate, Palmolive and Ajax, and an impressive history of dividend growth spanning more than 50 years, this defensive stock deserves the full attention of cautious investors.
The portfolio's disappointing performance has prompted us to refocus on our investment strategy of regular dividends, while maintaining a long-term view. In the face of current market volatility and a weak dollar, it is crucial to maintain a realistic and disciplined approach, staying true to our objective of investing in quality stocks.
Discover our detailed analysis of Sanofi Aventis, the world's 5th largest pharmaceutical group, and its attractiveness as a dividend stock. The stock, trading at attractive prices with a yield of 5.16% in 2011, has attractive characteristics despite its relative youth compared to other major players in the sector.
Français